Liquid biopsy-based longitudinal monitoring of copy number variations in six biomarker genes reveals exploratory associations with disease progression and treatment resistance in localized soft tissue sarcomas
Eurasian Journal of Medicine and Oncology · 16.11.2026 · 026260300
DOI: 10.36922/ejmo026260300 ↗Kurz gefasst
Fachartikel in der Zeitschrift Eurasian Journal of Medicine and Oncology, online erschienen am 16.11.2026. Verfasst von Aneta Borkowska und 12 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Soft tissue sarcomas (STS) are rare cancers without validated biomarkers for monitoring or prognosis. Liquid biopsy (LB) enables minimally invasive tumor tracking.
Objectives
This study aims to identify prognostic biomarkers in STS by assessing whether copy number variations (CNVs) of key genes correlate with outcomes, enabling early risk stratification and monitoring.
Methods
We conducted a preliminary longitudinal CNV analysis in plasma cell-free DNA from 19 patients using droplet digital polymerase chain reaction, measuring CNVs at multiple treatment stages (B1–B6). Statistical analyses were performed in R (v.4.4.3). Continuous variables are shown as median (interquartile range), and categorical variables as counts (%). Benjamini–Hochberg adjustment was applied, and progression-free survival (PFS) was analyzed using Kaplan–Meier and the log-rank test.
Results
Associations between CNVs and tumor size, necrosis, treatment response, disease progression, and PFS were observed. B1–B4 showed interconnected CNVs, involving TP53, RB1, MDM2, BRAF, MET, and HSP90. Progression may be associated with elevated CNVs for MDM2 and MET during chemotherapy (B2), and for TP53, RB1, MDM2, and HSP90 following radiotherapy (B3). At baseline, MDM2 CNV was higher in non-responders and increased during therapy in patients who subsequently experienced progression, which may be associated with poorer response to chemotherapy and radiotherapy. A p-value minimization framework suggested gene-specific CNV thresholds at B2 and B3, with higher CNV linked to shorter PFS.
Conclusion
Longitudinal LB profiling indicates that genomic changes in STS are linked to outcomes and resistance. MDM2 emerged as a potential biomarker. Given the small, exploratory study cohort, these findings need cautious interpretation and validation in larger groups.
Zitieren
APA
Borkowska, A., Szczepińska, T., Sitek, M., Trynkos, W., Ziuzia-Graczyk, I., Staniszewska, A., Kuryk, Ł., Kala, D., Kala, D., Bidstrup, E. H., Bidstrup, E. H., Rutkowski, P., & Staniszewska, M. (2026). Liquid biopsy-based longitudinal monitoring of copy number variations in six biomarker genes reveals exploratory associations with disease progression and treatment resistance in localized soft tissue sarcomas. Eurasian Journal of Medicine and Oncology, 0(0), 026260300. https://doi.org/10.36922/ejmo026260300
Vancouver
Borkowska A, Szczepińska T, Sitek M, Trynkos W, Ziuzia-Graczyk I, Staniszewska A, et al. Liquid biopsy-based longitudinal monitoring of copy number variations in six biomarker genes reveals exploratory associations with disease progression and treatment resistance in localized soft tissue sarcomas. Eurasian Journal of Medicine and Oncology. 2026;0(0):026260300. doi:10.36922/ejmo026260300
BibTeX
@article{Borkowska2026,
author = {Borkowska, Aneta and Szczepińska, Teresa and Sitek, Michał and Trynkos, Wiktoria and Ziuzia-Graczyk, Izabela and Staniszewska, Anna and Kuryk, Łukasz and Kala, Deepak and Kala, Deepak and Bidstrup, Ewelina Holm and Bidstrup, Ewelina Holm and Rutkowski, Piotr and Staniszewska, Monika},
title = {Liquid biopsy-based longitudinal monitoring of copy number variations in six biomarker genes reveals exploratory associations with disease progression and treatment resistance in localized soft tissue sarcomas},
journal = {Eurasian Journal of Medicine and Oncology},
year = {2026},
volume = {0},
number = {0},
pages = {026260300},
doi = {10.36922/ejmo026260300}
}
EUVIMED